ClinicalTrials.gg
Not yet recruitingNCT06116643Updated Nov 3, 2023

Pilot Study of a New Medical Food in the Management of Ulcerative Colitis

A Phase 1 interventional study of Soluble protein hydrolysate (SPHi) in Ulcerative Colitis, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 7 Years to 18 Years. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Stanford University · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
7 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Colitis, Ulcerative by Stanford University — 3 open to participants now, 3 under way, none of them phase 3. Colitis, Ulcerative · Stanford University.

Started
2023
the only one that year
Phase 1
5 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Colitis, Ulcerative by Stanford University, this one is the only one that started in 2023, is one of 5 in phase 1, and was the 10th registered.

Colitis, Ulcerative

1,857 studies on the registry are indexed under Colitis, Ulcerative; 472 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

3 of the 10 studies in Colitis, Ulcerative by Stanford University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 305 Colitis, Ulcerative studies recruiting now, 135 (44%) set no upper age limit and 134 (44%) stop at 75 or younger; 70 take children under 18; 41 take healthy volunteers.

This study: 7 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Colitis, Ulcerative by Stanford University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine at how well a new medical food works in managing inflammation associated with ulcerative colitis in children. The main question it aims to answer is:

  1. How well does the new medical food lower an inflammatory biomarker known as fecal calprotectin (fCal) in ulcerative colitis as compared to the historical active therapy levels of fCal? Participants will take a specified dose of the medical food in water each day for 12 weeks. The level of fCal will be measured through a stool sample at baseline, one during the 12 weeks, at the end of 12 weeks, and once more at 16 weeks. The levels of fCal will be compared across the 16 weeks and compared with levels before the new medical food was taken.
Read the detailed description

The objective of this clinical trial is to assess the physiological response to a biologic food substance in maintenance therapy for ulcerative colitis in children. This will be measured through the measurement of fecal calprotectin (fCal) levels across the study period as well as in comparison to historical active therapy levels. Secondary endpoints will include a variety of biologic markers (inflammatory, microbial, metabolic) as well as clinical scores including patient reported outcomes and serum-based biomarkers such as ferritin and hemoglobin. The aim is to evaluate the effectiveness of the medical food as a safe and well-tolerated non-pharmacologic approach for reducing dependence on drug therapies and their associated side effects in the treatment of ulcerative colitis.

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
7 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Pediatric patients with a confirmed diagnosis of ulcerative colitis on stable maintenance therapy.

Exclusion criteria

Exclusion Criteria:

Pediatric patients with a confirmed diagnosis of ulcerative colitis who utilize oral or topical in maintenance therapy.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Standard Active Therapy plus SPHi

    Participants will undergo the standard active therapy of ulcerative colitis plus the addition of the ProGo medical food.

    Dietary Supplement: Soluble protein hydrolysate (SPHi)

Interventions

  • Dietary supplementSoluble protein hydrolysate (SPHi)

    Participants that are already on stable maintenance therapy for ulcerative colitis will continue with their therapy regimen and the addition of 10g of SPHi in 100ml of water every day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Fecal Calprotectin Levels

    Level of fecal calprotectin in stool sample at each study visit and compared to historical active therapy fecal calprotectin levels.

    Time frame: Enrollment through the post end of treatment follow-up at 16 weeks.

07

Study locations

1 site
  • Lucile Packard Children's Hospital and Clinics
    Palo Alto, California 94304, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2023; primary completion for Dec 2025, 24 months later.

Of 84 phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 3, 2023
StartEst.
Dec 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06116643
Responsible party
Karl Sylvester (Professor-University Med Line, Stanford University) — Principal investigator
First posted
Nov 3, 2023
Start date
Dec 2023 (estimated)
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Nov 3, 2023

Study contacts

Karl Sylvester, MD
Contact
karls@stanford.edu
650-723-6439
Elena Harnish, MA
Contact
eharnish@stanford.edu
650-723-6439

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion